Title:
安全を確保しながら転移性がんまで効果的に治療可能な、搭載する免疫誘導遺伝子の最適発現レベルを与える発現制御システムを有する腫瘍溶解性ウイルス（腫瘍溶解性免疫治療）
Document Type and Number:
Japanese Patent JP7277926
Kind Code:
B2
Abstract:
The present invention is based on a novel concept for finding the optimum expression level of a therapeutic gene for inducing the largest therapeutic effect without any adverse reaction. An object of the present invention is to develop an immuno-viral therapeutic vector exerting the optimal therapeutic effect while ensuring high safety. The present invention provides, for example, an oncolytic virus comprising an immunity-inducing gene operably linked to the downstream of E2F promoter or a promoter having an activity equivalent thereto, wherein at least one promoter for nucleic acids encoding an element essential for viral replication or assembly is replaced with a promoter for an organ specific highly expressed factor or with a promoter for a cancer cell specific highly expressed factor.
Inventors:
Kenichiro Obasu
Nobuhiro Ijichi
Nobuhiro Ijichi
Application Number:
JP2019552379A
Publication Date:
May 19, 2023
Filing Date:
November 08, 2018
Export Citation:
Assignee:
Kagoshima University, a national university corporation
International Classes:
C12N7/01; A61K35/761; A61K35/768; A61P35/00; A61P37/04; C12N15/19; C12N15/27; C12N15/86; C12N15/861
Domestic Patent References:
| JP2016522805A | ||||
| JP2013532977A |
Foreign References:
| US20050186178 | ||||
| WO2012043710A1 | ||||
| WO2005012536A1 |
Other References:
ZHU Mingzhu, et al.,Linked Tumor-Selective Virus Replication and Transgene Expression from E3-Containing Oncolytic Adenoviruses,J. Virol.,2005年,Vol.79, No.9,pp.5455-5465
BRISTOL J. Andrew, et al.,In Vitro and in Vivo Activities of an Oncolytic Adenoviral Vector Designed to Express GM-CSF,Mol. Ther.,2003年,Vol.7, No.6,pp.755-764
小戝健一郎,多因子増殖制御型アデノウイルスの開発と実用化の展望,実験医学,2016年,Vol.34, No.1,pp.19-25
BRISTOL J. Andrew, et al.,In Vitro and in Vivo Activities of an Oncolytic Adenoviral Vector Designed to Express GM-CSF,Mol. Ther.,2003年,Vol.7, No.6,pp.755-764
小戝健一郎,多因子増殖制御型アデノウイルスの開発と実用化の展望,実験医学,2016年,Vol.34, No.1,pp.19-25
Attorney, Agent or Firm:
Shinsuke Umeda
Yuko Matsutoya
Yuko Matsutoya